Be Wise All, Take Xyzal at Night

Executive Summary

Challenger brand Xyzal outpaces category giants.
With virtually no awareness as a prescription, significantly outspent and a difficult-to-pronounce name, Xyzal needed to disrupt a mature category. Xyzal uncovered an unmet need – the impact of allergies on sleep and next day. Our distinctive campaign featuring our spokes-owl focused on a “smarter way to treat”, changing the treatment paradigm to night. Primary goal – drive brand sales above category. Xyzal sales grew nearly 2x category – 8.4% Xyzal vs. 4.8% – and has outpaced category every month for past 13 months!

Award — Gold
Award Year — 2023
Category — David vs. Goliath - Products
00:00
00:00

Client

Sanofi

Haven Cockerham, Head of Global Allergy
Jordana Barish, Global Sub-Category Head, Allergy
William Ulrick, Head of Content and Creative Excellence
Cecile Angeles , Senior Manager Allergy Portfolio
Vincent Balagat, Sr. Portfolio Lead, Allergy
Danielle Prencipe, Brand Lead
Jennifer Cleary, Commercial Innovation Lead
Richard Qian, Brand Lead

Lead Agency

PureRED

Mark Borcherding, Executive Creative Director
Christine McManus, EVP Client Partner
Bob Friedman, Director, Strategy
Adrienne Haas, Group Account Director
Valerie Perna, Creative Director
Arielle Shorr, ACD/Writer
Vince Travisano, Executive Creative Director
Laura Bunk, Account Director
Jamison Anthony, ACD/Writer
Adreanna Santos, Art Director
Jon Howarth, Art Director
Erin Scott, Account Executive

Contributing Companies

Havas Media

Brittany Moten, Director, Connections Planning
Patrick Fraser, VP, Group Director
Cristina Schlobohm, VP, Comms Planning

Ipsos Havas Media U.S.
Advertiser(s)
Xyzal
Markets Ran
United States
Language
English
Classification
National
Region
North America
Award Level
Gold
Industry Sector
Health & Wellness
Program
United States
Share Download PDF